UEGW 2021 Highlights Podcast

In this episode (19:31 min), Medicom’s correspondent covers 6 presentations from the United European Gastroenterology Week (UEGW 2021), held virtually 3–5 October 2021. It was extremely interesting with over 770 presentations and 450 speakers!

The topics discussed are:  

1.      Serologic response to COVID-19 mRNA vaccine reduced in IBD patients on anti-TNFα

Patients with inflammatory bowel disease (IBD) treated with an anti-TNFα showed a significantly reduced immune response to COVID-19 mRNA vaccines compared with IBD patients not on anti-TNFα treatment and healthy controls. The results of this prospective, observational, multicentre study suggest that IBD patients treated with anti-TNFα could benefit from a third dose of an mRNA vaccine.

2.      Filgotinib demonstrates promising results for various lines of therapy in UC

Both biologic-naïve and biologic-experienced patients with moderately to severely active ulcerative colitis (UC) achieved clinical remission more frequently when treated with filgotinib compared with placebo at weeks 10 and 58 of the phase 2b/3 SELECTION trial. In addition, the results at week 58 suggest that patients who had failed multiple biologics (of different mechanisms of action [MoA]) previously, could benefit from a treatment with high-dose filgotinib.

3.      Ritlecitinib and brepocitinib are promising JAK inhibitors for UC

Ritlecitinib and brepocitinib showed significant patient benefits over placebo at 8 weeks of the 32-week, phase 2b, induction-maintenance VIBRATO umbrella trial in a moderately to severely active ulcerative colitis (UC) population. The safety profiles of ritlecitinib and brepocitinib were favourable, and no clinically meaningful trends for changes in vital signs, laboratory parameters, or ECGs could be detected.

4.      Risankizumab meets primary endpoints in maintenance study for CD patients

Clinical remission was sustained throughout the 52-week FORTIFY maintenance study for patients with Crohn’s Disease (CD) who responded well to risankizumab induction therapy. Moreover, endoscopic remission and deep remission endpoints revealed a consistent dose-response relationship of continued risankizumab use. Risankizumab showed a favourable safety profile and was generally well tolerated.

5.      First pharmacological therapy with clear efficacy in coeliac disease patients

The administration of ZED-1227 demonstrated clinical and histological efficacy in patients with coeliac disease. This is the first pharmacological therapy for coeliac disease patients that showed efficacy in a phase 2a trial. Moreover, no important side effects were reported. A phase 2b/3 trial will be conducted among symptomatic coeliac disease patients at the end of this year to investigate the full potential of this new agent.

6.   Long-term efficacy data of dupilumab for eosinophilic oesophagitis

Dupilumab showed maintained patient benefits in an eosinophilic oesophagitis (EoE) population. The 28-week extended treatment period of the randomised, double-blind, placebo-controlled, phase 3 LIBERTY EoE TREET trial showed sustained symptomatic, histologic, and endoscopic benefits of dupilumab. The drug was well tolerated, and few severe adverse events were reported.

Enjoy listening!

Copyright ©2021 Medicom Medical Publishers



Posted on 20 October 202127 June 2024